Research ArticleAccepted Articles
Open Access
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund and Anna-Birgitte Aga
The Journal of Rheumatology November 2022, jrheum.220645; DOI: https://doi.org/10.3899/jrheum.220645
Imane Bardan
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Karen Minde Fagerli
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Joe Sexton
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Tore K. Kvien
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Gunnstein Bakland
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Pawel Mielnik
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Yi Hu
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Gunhild Lien
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Berit Flatø
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Øyvind Molberg
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Eirik Klami Kristianslund
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Anna-Birgitte Aga
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Article Information
jrheum.220645
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online November 15, 2022.
Article Versions
- You are currently viewing a Latest version of this article (November 15, 2022 - 04:00).
- latest version (February 1, 2023 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2022 The Journal of Rheumatology
Author Information
- Imane Bardan,
- Karen Minde Fagerli,
- Joe Sexton,
- Tore K. Kvien,
- Gunnstein Bakland,
- Pawel Mielnik,
- Yi Hu,
- Gunhild Lien,
- Berit Flatø,
- Øyvind Molberg,
- Eirik Klami Kristianslund and
- Anna-Birgitte Aga
-
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway.
Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund, Anna-Birgitte Aga
The Journal of Rheumatology Nov 2022, jrheum.220645; DOI: 10.3899/jrheum.220645
Accepted manuscript
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund, Anna-Birgitte Aga
The Journal of Rheumatology Nov 2022, jrheum.220645; DOI: 10.3899/jrheum.220645